content: UNITED STATES
  
                         SECURITIES AND EXCHANGE COMMISSION
  
                               WASHINGTON, D.C. 20549
  
  
          -----------------------------------------------------------------
  
  
                                      FORM 8-K
  
                                   CURRENT REPORT
  
                       PURSUANT TO SECTION 13 OR 15(d) OF THE
                           SECURITIES EXCHANGE ACT OF 1934
  
           Date of report (Date of earliest event reported): June 20, 2006
                                                             -------------
                                 CYTOGEN CORPORATION
        --------------------------------------------------------------------
                 (Exact Name of Registrant as Specified in Charter)
  
            Delaware                        000-14879               22-2322400
  ------------------------------    ------------------------   -------------------
   (State or Other Jurisdiction     (Commission File Number)    (I.R.S. Employer
        of Incorporation)                                      Identification No.)
  
      650 College Road East, CN 5308, Suite 3100, Princeton, NJ          08540
  ---------------------------------------------------------------    -------------
            (Address of Principal Executive Offices)                   (Zip Code)
  
         Registrant's telephone number, including area code: (609) 750-8200
                                                             --------------
  
  
  --------------------------------------------------------------------------------
            (Former Name or Former Address, if Changed Since Last Report)
  
  
       Check the  appropriate  box below if the Form 8-K  filing  is  intended  to
  simultaneously  satisfy the filing obligation of the registrant under any of the
  following provisions (see General Instruction A.2. below):
  
       |_|  Written  communications  pursuant to Rule 425 under the Securities Act
  (17 CFR 230.425)
  
       |_|  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
  CFR 240.14a-12)
  
       |_|  Pre-commencement  communications  pursuant to Rule 14d-2(b)  under the
  Exchange Act (17 CFR 240.14d-2(b))
  
       |_|  Pre-commencement  communications  pursuant to Rule 13e-4(c)  under the
  Exchange Act (17 CFR 240.13e-4(c))
  
  
  <PAGE>
  
  
  ITEM 5.02   DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF DIRECTORS;
              APPOINTMENT OF PRINCIPAL OFFICERS.
  
  
       On June 20,  2006,  Cytogen  Corporation  (the  "Company")  announced  that
  Christopher P. Schnittker,  Senior Vice President and Chief Financial Officer of
  the Company,  has resigned  from the Company  effective  June 20, 2006 to pursue
  other career opportunities.
  
       The full text of the June 20, 2006 press release issued in connection  with
  the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K.
  
       Thu A. Dang, the Company's Vice President, Finance, will serve as principal
  financial officer and principal  accounting officer until a replacement has been
  found.  Ms.  Dang has served as the  Company's  Vice  President,  Finance  since
  January 2003. Ms. Dang joined the Company in September 1988 as Senior  Financial
  Reporting Accountant, and was promoted to Director of Finance in May 2000. Prior
  to joining the Company, Ms. Dang held numerous positions with Harrisburg Dairies
  for six years,  serving  ultimately as their  Controller.  Ms. Dang holds a B.S.
  degree in Accounting from Elizabethtown College.
  
  
  ITEM 9.01   FINANCIAL STATEMENTS AND EXHIBITS.
  
  (d)  Exhibits.
  
       Exhibit No.                          Description
       -----------                          -----------
  
           99.1          Press Release of Cytogen Corporation dated June 20, 2006.
  
  
  
  <PAGE>
  
  
                                     SIGNATURES
  
  
       Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
  Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
  undersigned hereunto duly authorized.
  
  
                                                  CYTOGEN CORPORATION
  
  
  
                                                  By:  /s/ Michael D. Becker
                                                     -----------------------------
                                                     Michael D. Becker
                                                     President and Chief Executive
                                                     Officer
  
  Dated:   June 20, 2006
  
  
  
  <PAGE>
  
  
                                    EXHIBIT INDEX
  
  
       Exhibit No.                          Description
       -----------                          -----------
  
           99.1          Press Release of Cytogen Corporation dated June 20, 2006.
metadata_documents: [{"type": "8-K", "sequence": "1", "filename": "form8k-062006_cfo.txt", "description": "FORM 8-K 062006 CFO", "secsgml_size_bytes": 4692}]
metadata_filer: {"company-data": {"conformed-name": "CYTOGEN CORP", "cik": "0000725058", "assigned-sic": "2834", "irs-number": "222322400", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-14879", "film-number": "06915557"}, "business-address": {"street1": "650 COLLEGE RD EAST STE 3100", "city": "PRINCETON", "state": "NJ", "zip": "08540", "phone": "6099878200"}, "mail-address": {"street1": "650 COLLEGE RD EAST STE 3100", "city": "PRINCETON", "state": "NJ", "zip": "08540"}}
text: UNITED STATES
  
                         SECURITIES AND EXCHANGE COMMISSION
  
                               WASHINGTON, D.C. 20549
  
          -----------------------------------------------------------------
  
                                      FORM 8-K
  
                                   CURRENT REPORT
  
                       PURSUANT TO SECTION 13 OR 15(d) OF THE
                           SECURITIES EXCHANGE ACT OF 1934
  
           Date of report (Date of earliest event reported): June 20, 2006
                                                             -------------
                                 CYTOGEN CORPORATION
        --------------------------------------------------------------------
                 (Exact Name of Registrant as Specified in Charter)
  
            Delaware                        000-14879               22-2322400
  ------------------------------    ------------------------   -------------------
   (State or Other Jurisdiction     (Commission File Number)    (I.R.S. Employer
        of Incorporation)                                      Identification No.)
  
      650 College Road East, CN 5308, Suite 3100, Princeton, NJ          08540
  ---------------------------------------------------------------    -------------
            (Address of Principal Executive Offices)                   (Zip Code)
  
         Registrant's telephone number, including area code: (609) 750-8200
                                                             --------------
  
  --------------------------------------------------------------------------------
            (Former Name or Former Address, if Changed Since Last Report)
  
       Check the  appropriate  box below if the Form 8-K  filing  is  intended  to
  simultaneously  satisfy the filing obligation of the registrant under any of the
  following provisions (see General Instruction A.2. below):
  
       |_|  Written  communications  pursuant to Rule 425 under the Securities Act
  (17 CFR 230.425)
  
       |_|  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
  CFR 240.14a-12)
  
       |_|  Pre-commencement  communications  pursuant to Rule 14d-2(b)  under the
  Exchange Act (17 CFR 240.14d-2(b))
  
       |_|  Pre-commencement  communications  pursuant to Rule 13e-4(c)  under the
  Exchange Act (17 CFR 240.13e-4(c))
  ITEM 5.02   DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF DIRECTORS;
              APPOINTMENT OF PRINCIPAL OFFICERS.
  
       On June 20,  2006,  Cytogen  Corporation  (the  "Company")  announced  that
  Christopher P. Schnittker,  Senior Vice President and Chief Financial Officer of
  the Company,  has resigned  from the Company  effective  June 20, 2006 to pursue
  other career opportunities.
  
       The full text of the June 20, 2006 press release issued in connection  with
  the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K.
  
       Thu A. Dang, the Company's Vice President, Finance, will serve as principal
  financial officer and principal  accounting officer until a replacement has been
  found.  Ms.  Dang has served as the  Company's  Vice  President,  Finance  since
  January 2003. Ms. Dang joined the Company in September 1988 as Senior  Financial
  Reporting Accountant, and was promoted to Director of Finance in May 2000. Prior
  to joining the Company, Ms. Dang held numerous positions with Harrisburg Dairies
  for six years,  serving  ultimately as their  Controller.  Ms. Dang holds a B.S.
  degree in Accounting from Elizabethtown College.
  
  ITEM 9.01   FINANCIAL STATEMENTS AND EXHIBITS.
  
  (d)  Exhibits.
  
       Exhibit No.                          Description
       -----------                          -----------
  
           99.1          Press Release of Cytogen Corporation dated June 20, 2006.
  SIGNATURES
  
       Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
  Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
  undersigned hereunto duly authorized.
  
                                                  CYTOGEN CORPORATION
  
                                                  By:  /s/ Michael D. Becker
                                                     -----------------------------
                                                     Michael D. Becker
                                                     President and Chief Executive
                                                     Officer
  
  Dated:   June 20, 2006
  EXHIBIT INDEX
  
       Exhibit No.                          Description
       -----------                          -----------
  
           99.1          Press Release of Cytogen Corporation dated June 20, 2006.